REVLIMID approved by the European Commission for the treatment of adult patients with previously untreated multiple myeloma

Celgene International Sàrl, a wholly owned subsidiary of Celgene Corporation, has announced that the European Commission (EC) has approved REVLIMID® (lenalidomide) for the treatment of adult… Source link